BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Nasonov EL, Lila AM, Mazurov VI, Belov BS, Karateev AE, Dubinina TV, Nikitinskaya OA, Baranov AA, Abdulganieva DI, Moiseev SV, Zagrebneva AI. Coronavirus Disease 2019 (COVID-19) and Immune-mediated Rheumatic Diseases. Recommendations of the Association of Rheumatologists of Russia. Naučno-praktičeskaâ revmatologiâ 2021;59:239-254. [DOI: 10.47360/1995-4484-2021-239-254] [Cited by in Crossref: 21] [Cited by in F6Publishing: 24] [Article Influence: 10.5] [Reference Citation Analysis]
Number Citing Articles
1 Nikitina NM, Aleksandrova OL, Magdeeva NA, Melekhina IF, Pasechnaya NV. Combination of granulomatosis with polyangiitis with COVID-19: difficulties in differential diagnosis and treatment. jour 2022;3:107-115. [DOI: 10.21886/2712-8156-2022-3-4-107-115] [Reference Citation Analysis]
2 Mazurov VI, Nasonov EL, Lila AM, Gaydukova IZ, Inamova OV, Leonchenkova NY. Problems associated with new coronavirus infection vaccination in patients with rheumatic diseases. HERALD of North-Western State Medical University named after I I Mechnikov 2022;14:39-51. [DOI: 10.17816/mechnikov108970] [Reference Citation Analysis]
3 Kulikov AN, Muravyeva NV, Belov BS. Safety of Gam-COVID-Vac (Sputnik V) Combined Vector Vaccine in Patients With Immunoinflammatory Rheumatic Diseases: Preliminary Data. A&Ch 2022;67:33-39. [DOI: 10.37489/0235-2990-2022-67-7-8-33-39] [Reference Citation Analysis]
4 Belov BB, Muravyeva NV, Kulikov AN. Immunogenicity of Vaccines Against SARS-CoV-2 In Patients With Rheumatic Diseases. A&Ch 2022;67:70-80. [DOI: 10.37489/0235-2990-2022-67-5-6-70-80] [Reference Citation Analysis]
5 Krichevskaya OA, Dubinina TV, Ilinykh EV, Demina AB, Andrianova IA. COVID-19 in women with ankylosing spondylitis during pregnancy and within one year after childbirth. Naučno-praktičeskaâ revmatologiâ 2022;60:413-419. [DOI: 10.47360/1995-4484-2022-413-419] [Reference Citation Analysis]
6 Aronova ES, Belov BS, Gridneva GI. Rheumatological manifestations of post-COVID syndrome (literature review). Medicinskij alfavit 2022. [DOI: 10.33667/2078-5631-2022-15-20-25] [Reference Citation Analysis]
7 Baimukhamedov CT, Botabekova AK, Dossybayeva GN, Makhmudov SA. Rheumatoid arthritis and post-COVID-19 syndrome. Naučno-praktičeskaâ revmatologiâ 2022;60:276-279. [DOI: 10.47360/1995-4484-2022-276-279] [Reference Citation Analysis]
8 Baimukhamedov CT, Botabekova AK, Dossybayeva GN, Makhmudov SA. Rheumatoid arthritis and post-COVID-19 syndrome. Naučno-praktičeskaâ revmatologiâ 2022;60:276-279. [DOI: 10.47360/1995-4484-2022-276-279] [Reference Citation Analysis]
9 Nasonov EL. Janus kinase inhibitors in immunoinflammatory rheumatic diseases. Terapevticheskii arkhiv 2022;94:605-609. [DOI: 10.26442/00403660.2022.05.201501] [Reference Citation Analysis]
10 Korolev MA, Letyagina EA, Sizikov AE, Bogoderova LA, Ubshaeva YB, Omelchenko VO, Akimova AA, Mullagaliev AA, Chumasova OA, Kurochkina YD. Immuno-inflammatory rheumatic diseases and COVID-19: analysis of clinical outcomes according to the data of the register of patients of the Novosibirsk region receiving therapy with genetically engineered biological drugs. Terapevticheskii arkhiv 2022;94:636-641. [DOI: 10.26442/00403660.2022.05.201502] [Reference Citation Analysis]
11 Sorotskaya VN, Plakhova AO, Halmuradova BB, Vaisman DS, Balabanova RM. Effect of COVID-19 coronavirus infection on the course of rheumatoid arthritis. Naučno-praktičeskaâ revmatologiâ 2022;60:157-161. [DOI: 10.47360/1995-4484-2022-157-161] [Reference Citation Analysis]
12 Karateev AE, Polishchuk EY, Potapova AS, Matyanova EV, Semashko AS, Bobkova АO, Filatova ES, Amirjanova VN, Glukhova SI, Zotkin EG, Lila AM. The use of biological disease-modifying antirheumatic drugs and Janus kinase inhibitors in rheumatoid arthritis during the COVID-19 coronavirus disease pandemic: data from a telephone survey of 254 patients. Naučno-praktičeskaâ revmatologiâ 2022;60:149-156. [DOI: 10.47360/1995-4484-2022-149-156] [Reference Citation Analysis]
13 Nasonov EL, Korotaeva TV. Janus kinase inhibitors in immunoinflammatory diseases: 10 years of clinical practice in rheumatology. Naučno-praktičeskaâ revmatologiâ 2022;60:131-148. [DOI: 10.47360/1995-4484-2022-131-148] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
14 Gordeev AV, Matyanova EV, Olyunin YA, Galushko EA, Zotkin EG. Difficult-to-treat rheumatoid arthritis in the clinical practice of a rheumatological hospital. First look. Sovremennaâ revmatologiâ 2022;16:13-20. [DOI: 10.14412/1996-7012-2022-2-13-20] [Reference Citation Analysis]
15 Vorobeva OV, Romanova LP. Organ changes after SARS-CoV-2 infection in a patient with systemic sclerosis according to autopsy. Sovremennaâ revmatologiâ 2022;16:69-73. [DOI: 10.14412/1996-7012-2022-2-69-73] [Reference Citation Analysis]
16 Belov BS, Popkova TV, Tarasova GM, Muravieva NV. Vaccination in persons with systemic lupus erythematosus: the current state of the problem. Sovremennaâ revmatologiâ 2022;16:7-12. [DOI: 10.14412/1996-7012-2022-2-7-12] [Reference Citation Analysis]
17 Nizyaeva N, Lomova N, Dolgopolova E, Karapetyan T, Petrova U, Shmakov R, Frankevich V. Detection of SARS-Cov-2 N-protein in Mesenchymal Cells of Umbilical Warton's Jelly in Women with COVID-19. BMCRM 2022;5:e00165. [DOI: 10.18097/bmcrm00165] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
18 Shostak NA, Klimenko AA, Demidova NA, Kondrashov AA, Andryashkina DY, Saakyan YM, Varaksin GA, Tarantina AY. Musculoskeletal manifectations of the new coronavirus infection: focus on arthralgia and myalgia. Klinicist 2022;15:31-41. [DOI: 10.17650/1818-8338-2021-15-1-4-k650] [Reference Citation Analysis]
19 Nasonov EL, Korotaeva TV, Selmi CF. Prospects for the use of monoclonal antibodies to interleukin 23 Gusеlkumab in psoriatic arthritis: New data. Naučno-praktičeskaâ revmatologiâ 2022;60:80-90. [DOI: 10.47360/1995-4484-2022-80-90] [Reference Citation Analysis]
20 Belov BS, Lila AM, Nasonov EL. Vaccination against SARS-CoV-2 in rheumatic diseases: Safety issues. Naučno-praktičeskaâ revmatologiâ 2022;60:21-31. [DOI: 10.47360/1995-4484-2022-21-31] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
21 Nasonov EL, Lila AM, Dubinina TV, Nikininskaya OA, Amirdjanova VN. Advances in rheumatology at the beginning of the 21st century. Naučno-praktičeskaâ revmatologiâ 2022;60:5-20. [DOI: 10.47360/1995-4484-2022-5-20] [Reference Citation Analysis]
22 Kulikov AN, Muravyeva NV, Belov BS. Safety of COVID-19 vaccines in patients with immunoinflammatory rheumatic diseases (preliminary data). Sovremennaâ revmatologiâ 2022;16:26-31. [DOI: 10.14412/1996-7012-2022-1-26-31] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
23 Drapkina OM, Shishkova VN, Berns SA, Gorshkov AY, Ryzhakova LN, Ivanova AA, Veretennikova AV. Vaccination against new coronavirus infection in patients with cardiovascular and autoimmune diseases. Kompleks probl serdečno-sosud zabol 2021;10:112-121. [DOI: 10.17802/2306-1278-2021-10-4-112-121] [Reference Citation Analysis]
24 Belov BS, Muravyeva NV, Baranova MM. Anti-inflammatory drugs and immunogenicity of vaccines in patients with rheumatic diseases. Medicinskij sovet 2021. [DOI: 10.21518/2079-701x-2021-19-177-187] [Reference Citation Analysis]
25 Nasonov EL, Avdeeva AS. B cell depletion in immune-mediated rheumatic diseases and coronavirus disease 2019 (COVID-19). Naučno-praktičeskaâ revmatologiâ 2021;59:384-393. [DOI: 10.47360/1995-4484-2021-384-393] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]